Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with stage III, stage IV, or relapsed lung cancer that has been confirmed by tissue biopsy.
- People aged 18 to 80 years old.
- People who have waited at least 4 weeks since their last chemotherapy or radiation treatment, and at least 2 weeks since last taking steroid or immune-suppressing medications.
- People whose side effects from chemotherapy have cleared up.
- People whose cancer cells have been tested and shown to have high levels of certain cancer-specific proteins (confirmed through lab testing of tissue samples).
- People with a general health and ability-to-function score of at least 50% on a standard medical scale (confirm with trial site).
- People with an expected survival of at least 6 weeks.
- People with blood counts within acceptable ranges — enough white blood cells and platelets as measured by a blood test.
- People with kidneys and liver functioning within acceptable ranges, based on blood tests.
- People with an oxygen level in the blood of 90% or above.
- People who have given written consent before any trial procedures begin.
Who may not be able to join:
- People whose airway is blocked by a tumour.
- People with a history of epilepsy or other brain or nervous system conditions.
- People who currently need steroid medications or other immune-suppressing treatments.
- People with a history of serious heart rhythm problems (specifically relating to a measurement called the QT interval — confirm with trial site).
- People with a history of serious side effects from a drug called cyclophosphamide.
- People who have taken part in another clinical drug trial or immune cell therapy study within the past 28 days.
- People whose liver or kidney function test results fall outside the acceptable ranges set by the trial.
- People who are pregnant or breastfeeding.
- People who have a serious active infection at the time of screening.
- People with active HIV, Hepatitis B, or Hepatitis C infection, or any other uncontrolled infection.
- People who, in the opinion of the trial investigators, may not be suitable or may have difficulty following the trial requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of engineered T cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.